Search - tctmd.com

Displaying 281 - 300 of 417

Sort: Relevancy | Date

Presentation TCT 2016

Symptomatic High-Risk Aortic Regurgitation: Is TAVR A Viable Alternative?

Presenter: A. Pieter Kappetein, Allan Schwartz, Hendrik Treede

October 30, 2016

Presentation TCT 2016

Leaflet Thickening, Dysfunction, and Thrombosis: Clinical Perspectives- Are Problems Under-Reported? Are the Changes a Class Effect?

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Raj Makkar

October 30, 2016

Presentation TCT 2016

Leaflet Thickening, Dysfunction, and Thrombosis: Latest Recommendations by the ISO Cardiac Valves Committee

Presenter: Carlos E. Ruiz, Ulrich Steinseifer

October 30, 2016

Presentation TCT 2016

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Presenter: A. Pieter Kappetein, Allan Schwartz, Martin B. Leon

October 30, 2016

Presentation TCT 2016

TVA Medical Approach

Presenter: Mitchell W. Krucoff, Katherine Kumar

October 30, 2016

Presentation TCT 2016

Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Howard C. Herrmann

October 30, 2016

Presentation TCT 2016

Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis

Presenter: A. Pieter Kappetein, Allan Schwartz, Philippe Pibarot

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls

Presenter: A. Pieter Kappetein, Allan Schwartz, Vinayak Bapat

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Presenter: A. Pieter Kappetein, Allan Schwartz, Danny Dvir

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Sara Takahashi

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Presenter: A. Pieter Kappetein, Allan Schwartz, Mathew Williams

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Rachel Neubrander

October 30, 2016

Presentation TCT 2016

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Kenneth Stein, MD

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Transcatheter Pulmonary Valve Replacement

Presenter: John G. Webb, Ajit Yoganathan, John P. Cheatham

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Advertisement

Symptomatic High-Risk Aortic Regurgitation: Is TAVR A Viable Alternative?

Leaflet Thickening, Dysfunction, and Thrombosis: Clinical Perspectives- Are Problems Under-Reported? Are the Changes a Class Effect?

Leaflet Thickening, Dysfunction, and Thrombosis: Latest Recommendations by the ISO Cardiac Valves Committee

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

TVA Medical Approach

Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR

Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis

TMVR Clinical Trial Design: Early Insights from Industry

Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

FDA Perspectives

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Lessons Learned from Early FIH/EFS Trials: Transcatheter Pulmonary Valve Replacement

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content